Recent Efforts in Identification of Privileged Scaffolds as Antiviral Agents

• Published in: Chemistry & biodiversity 2023-10, Vol.20 (10), p.e202300921-n/a
• Main Authors: Yadav, Yogesh, Singh, Kavita, Sharma, Sunil, Mishra, Vinay Kumar, Sagar, Ram
• Format: Article
• Language: English
• Subjects: Anti-HIV; Anti-SARS; Antiviral agents; Drug development; Drug resistance; Drugs; Exo-a-sialidase; Hepatitis; HIV; Human immunodeficiency virus; Molecular docking; Natural products; Neuraminidase; Scaffolds; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Viral diseases; Viral infections
• ISSN: 1612-1872; 1612-1880
• DOI: 10.1002/cbdv.202300921

Viral infections are the most important health concern nowadays to mankind, which is unexpectedly increasing the health complications and fatality rate worldwide. The recent viral infection outbreak developed a pressing need for small molecules that can be quickly deployed for the control/treatment of re‐emerging or new emerging viral infections. Numerous viruses, including the human immunodeficiency virus (HIV), hepatitis, influenza, SARS‐CoV‐1, SARS‐CoV‐2, and others, are still challenging due to emerging resistance to known drugs. Therefore, there is always a need to search for new antiviral small molecules that can combat viral infection with new modes of action. This review highlighted recent progress in developing new antiviral molecules based on natural product‐inspired scaffolds. Herein, the structure‐activity relationship of the FDA‐approved drugs along with the molecular docking studies of selected compounds have been discussed against several target proteins. The findings of new small molecules as neuraminidase inhibitors, other than known drug scaffolds, Anti‐HIV and SARS‐CoV are incorporated in this review paper.